---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-096047"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2025-10-02T23:59:59+00:00"
generated_at: "2026-05-17T05:00:44.467323+00:00"
event_type: "other"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Theriva Biologics cuts 32% of workforce, expects $520K severance costs, extends cash runway into Q2 2026

## Summary
- Board approved restructuring plan to focus on business development and VCN-01 clinical trials for PDAC and retinoblastoma.
- Workforce reduction of ~7 employees (32% of global workforce) implemented September 30, 2025.
- Estimated $520K in cash severance and benefits charges in Q4 2025; expects ~$2M annual compensation savings.
- Cash runway extended into Q2 2026 due to cost reductions and anticipated operating savings.

## SEC filing metadata
- accession: 0001104659-25-096047
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2025-10-02T23:59:59+00:00
- event_type: other
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465925096047/0001104659-25-096047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465925096047/tm2527561d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-096047
- JSON: https://secwatch.observer/filing/0001104659-25-096047.json
- Plain text: https://secwatch.observer/filing/0001104659-25-096047.txt

## Source-grounded claims
- claim_id: 4c62e1e733757f342ca395801422ff8bd8df458e
  claim: Theriva Biologics, Inc. announced a restructuring with charges of approximately $520,000 affecting global Company workforce (approximately seven employees or 32% of the current global Company workforce).
  evidence_excerpt: its best opportunity for success. The Company expects to substantially complete the employee reduction immediately and estimates that it will incur a total of approximately $520,000 in charges in connection with the workforce reduction, all of which is expected to be incurred in the fourth quarter of 2025. These charges consist primarily of cash severance and
  evidence_url: https://www.sec.gov/Archives/edgar/data/894158/000110465925096047/0001104659-25-096047-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.